EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter randomised phase-III trial to compare tumour nephrectomy plus adjuvant autologous tumour cell-lysate vaccine versus tumour nephrectomy without adjuvant treatment for renal cell carcinoma pT2-3bpNO-3M0



Multicenter randomised phase-III trial to compare tumour nephrectomy plus adjuvant autologous tumour cell-lysate vaccine versus tumour nephrectomy without adjuvant treatment for renal cell carcinoma pT2-3bpNO-3M0



European Urology Supplements 2(1): 99, February




(PDF 0-2 workdays service: $29.90)

Accession: 035349893

Download citation: RISBibTeXText



Related references

Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Folia Biologica 49(2): 69-73, 2003

Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma, , Abstracted from: Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.Lancet 2004;363:594599. Cancer Treatment Reviews 30(6): 589-593, 2004

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363(9409): 594-599, 2004

Multicenter phase-III trial of adjuvant autologous tumor cell-lysate vaccine versus no adjuvant treatment in patients with non-metastasized renal cell carcinoma after radical nephrectomy A 3-year analysis. Journal of Urology 167(4 Supplement): 166-167, April, 2002

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633): 145-154, 2008

An adjuvant autologous renal tumor cell vaccine reduces the risk of progression in patients with renal cell carcinoma following radical nephrectomy Final results of a multicenter phase-III trial. Journal of Urology 171(4 Supplement): 435, April, 2004

Adjuvant Treatment With Interleukin-2- and Interferon-alpha2a-Based Chemoimmunotherapy in Renal Cell Carcinoma Post Tumour Nephrectomy: Results of a Prospectively Randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Yearbook of Urology 2006: 150-151, 2006

Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). British Journal of Cancer 92(5): 843-846, 2005

Value of cytoreductive tumour nephrectomy in conjunction with immunotherapy in metastatic renal cell carcinoma Results of a randomised phase III trial. European Urology 37(Suppl 2): 55, March, 2000

Autologous tumor cell vaccine as an adjuvant treatment and effect of auto-tumour vaccine replantation on the immunological function of malignant solid tumour patients. Zhongguo Zhongliu Linchuang 30(11): 769-771, March, 2003

Re: ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. European Urology 61(1): 219-220, 2012

Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunology, ImmunoTherapy 59(5): 687-695, 2010

Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy. Der Urologe. Ausg. A 50(4): 489-492, 2011

Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma. European Urology 46(3): 327-330, 2004

Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). Bmj Open 8(8): E021701-E021701, 2018